The ATTRACT study will evaluate the safety, tolerability, and preliminary efficacy of ATG-201 monotherapy in adult patients struggling with B cell-related autoimmune conditions. Researchers plan to execute the trial in two distinct stages: dose escalation to determine the recommended Phase II dose, followed by a dose expansion phase. Beyond safety monitoring, the study will track pharmacokinetic and pharmacodynamic profiles to gauge how effectively the treatment interacts with the body's immune system.
Antengene Cleared to Start Australian Phase I Trials for ATG-201
Antengene Corporation has secured approval from Australia’s Human Research Ethics Committee to initiate the Phase I ATTRACT clinical study for ATG-201. This bispecific T-cell engager, designed to target CD19-expressing B cells, represents a strategic shift for the biotech firm as it expands its focus into autoimmune disease treatment.
This Australian clearance follows a June approval from China's National Medical Products Administration, signaling a synchronized multi-regional development strategy. Under a partnership agreement, UCB holds the exclusive worldwide rights to develop and commercialize the asset. By utilizing its proprietary AnTenGager platform, Antengene aims to refine the drug's binding kinetics to minimize potential side effects like cytokine release syndrome while maintaining high precision against pathogenic B cells.
Comments (0)
No comments yet. Be the first!